tetano
Editor, Senior Moderator
Bioeng Transl Med
. 2024 Jun 3;9(5):e10689.
doi: 10.1002/btm2.10689. eCollection 2024 Sep. Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity
Shiho Chiba[SUP] 1 2 [/SUP], Tadashi Maemura[SUP] 1 [/SUP], Kathryn Loeffler[SUP] 3 [/SUP], Steven J Frey[SUP] 3 [/SUP], Chunyang Gu[SUP] 1 [/SUP], Asim Biswas[SUP] 1 [/SUP], Masato Hatta[SUP] 1 [/SUP], Yoshihiro Kawaoka[SUP] 1 2 4 5 [/SUP], Ravi S Kane[SUP] 3 [/SUP]
Affiliations
Vaccination is the most effective strategy to combat influenza. Ideally, potent and persistent vaccine effects would be induced with a single vaccine dose. Here, we designed a virus-like particle (VLP)-based vaccine presenting multiple copies of the influenza hemagglutinin (HA) from A/Puerto Rico/8/1934 (PR8HA-VLP) and examined its immunogenicity and protective efficacy in ferrets. Serum-neutralizing antibodies were effectively induced against the homologous virus at 3-week post-vaccination with a single dose of PR8HA-VLP with or without adjuvants. When the single-immunized ferrets were challenged with the homologous virus, virus replication in the nasal mucosa was significantly reduced. Long-term monitoring of serum titers revealed that after adjuvanted vaccination with PR8HA-VLP, neutralizing antibodies were retained at similar levels 20- to 183-week post-vaccination, although a 4- to 8-fold titer decline was observed from 3- to 20-week post-vaccination. Boost immunization at 183 weeks after the first immunization elicited higher neutralizing antibody titers than those at 3 weeks after the initial immunization in most of the animals. These results confirm that nanoparticle-based vaccines are a promising approach to effectively elicit durable multiyear neutralizing antibody responses against influenza viruses.
Keywords: VLP‐based vaccine; adjuvant; duration of immunity; ferret; influenza A virus; neutralizing antibody titers; virus‐like particles (VLPs).
. 2024 Jun 3;9(5):e10689.
doi: 10.1002/btm2.10689. eCollection 2024 Sep. Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity
Shiho Chiba[SUP] 1 2 [/SUP], Tadashi Maemura[SUP] 1 [/SUP], Kathryn Loeffler[SUP] 3 [/SUP], Steven J Frey[SUP] 3 [/SUP], Chunyang Gu[SUP] 1 [/SUP], Asim Biswas[SUP] 1 [/SUP], Masato Hatta[SUP] 1 [/SUP], Yoshihiro Kawaoka[SUP] 1 2 4 5 [/SUP], Ravi S Kane[SUP] 3 [/SUP]
Affiliations
- PMID: 39553436
- PMCID: PMC11561850
- DOI: 10.1002/btm2.10689
Vaccination is the most effective strategy to combat influenza. Ideally, potent and persistent vaccine effects would be induced with a single vaccine dose. Here, we designed a virus-like particle (VLP)-based vaccine presenting multiple copies of the influenza hemagglutinin (HA) from A/Puerto Rico/8/1934 (PR8HA-VLP) and examined its immunogenicity and protective efficacy in ferrets. Serum-neutralizing antibodies were effectively induced against the homologous virus at 3-week post-vaccination with a single dose of PR8HA-VLP with or without adjuvants. When the single-immunized ferrets were challenged with the homologous virus, virus replication in the nasal mucosa was significantly reduced. Long-term monitoring of serum titers revealed that after adjuvanted vaccination with PR8HA-VLP, neutralizing antibodies were retained at similar levels 20- to 183-week post-vaccination, although a 4- to 8-fold titer decline was observed from 3- to 20-week post-vaccination. Boost immunization at 183 weeks after the first immunization elicited higher neutralizing antibody titers than those at 3 weeks after the initial immunization in most of the animals. These results confirm that nanoparticle-based vaccines are a promising approach to effectively elicit durable multiyear neutralizing antibody responses against influenza viruses.
Keywords: VLP‐based vaccine; adjuvant; duration of immunity; ferret; influenza A virus; neutralizing antibody titers; virus‐like particles (VLPs).